Interpace Diagnostics Ranked as Top 10 Bioinformatics Solutions Provider
December 27 2018 - 5:55AM
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced
today that CIO Applications, a publication focused on providing
professionals with information on the most comprehensive collection
of technology trends, has once again recognized Interpace
Diagnostics as a top bioinformatics solutions company. This year
CIO Applications ranked Interpace as a Top 10 Company for providing
bioinformatics solutions through the Company’s extensive database
of molecular testing results. In 2017, Interpace was recognized as
a Top 20 Bioinformatics Solutions Provider. CIO Applications
utilizes its distinguished selection panel, comprised of CEOs,
CIOs, CTOs, industry analysts and its own editorial board to narrow
the final list of 10 bioinformatics solutions providers which this
year includes Interpace and selected prominent companies such as
Biomax Informatics, Codexis and Oxford Gene Technology. These
companies are all known to exhibit competence in delivering
best-in-class bioinformatics capabilities according to the
selection panel.
Bioinformatics is becoming more and more
critical in the drug discovery market as bioinformatics solution
providers transform the development, testing, and application of
the modeling and analysis of biological data derived from the
molecular profiling of specific patient populations. Interpace
currently has a biobank containing nearly 50,000 patient samples
and the associated bioinformatics database including clinical and
molecular analysis and results. The biobank includes data elements
across a wide array of cancer types including pancreatic, thyroid,
esophageal, and lung. In anticipation of the growing bioinformatics
market, Interpace continues to explore opportunities to access and
leverage these data sets to assist in developing novel
therapeutics.
Jack Stover, President and CEO of Interpace,
stated, “We were pleased to be recognized again by CIO Applications
as a top bioinformatics solutions provider and especially now as a
top 10 provider recognizing the value of our core biomarker and DNA
analysis as well as our biobank and associated databases.”
The full article can be found at:
https://www.interpacediagnostics.com/news-media/in-the-news
About Interpace Diagnostics Group, Inc.
Interpace is a fully integrated commercial and
bioinformatics company that provides clinically useful molecular
and related first line diagnostic tests and pathology services for
evaluating risk of cancer by leveraging the latest technology in
personalized medicine for improved patient diagnosis and
management. The Company currently has four commercialized molecular
tests and one test in a clinical evaluation process (CEP);
PancraGEN® for the diagnosis and prognosis of pancreatic cancer
from pancreatic cysts; ThyGeNEXT® for the diagnosis of thyroid
cancer from thyroid nodules utilizing a next generation sequencing
assay; ThyraMIR® for the diagnosis of thyroid cancer from thyroid
nodules utilizing a proprietary gene expression assay; and
RespriDx™, that differentiates lung cancer of primary vs.
metastatic origin. The Company’s data base includes data from over
45,000 patients who have been tested using the Company’s current
products, including over 15,000 molecular tests for thyroid
nodules. Interpace has been designated by CIO Applications magazine
as one of the top 10 companies for providing bioinformatics
solutions. Interpace’s mission is to provide personalized medicine
through molecular diagnostics, innovation and data to advance
patient care based on rigorous science. For more information,
please visit Interpace’s website at
www.interpacediagnostics.com
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, relating to the
Company's future financial and operating performance, competitive
and market conditions and future business decisions, all of which
are difficult or impossible to predict accurately and many of which
are beyond the Company's control. These statements also involve
known and unknown risks, uncertainties and other factors that may
cause the Company's actual results to be materially different from
those expressed or implied by any forward-looking statement. Known
and unknown risks, uncertainties and other factors include, but are
not limited to, the Company’s history of losses, the Company's
ability to adequately finance the business, the market's acceptance
of its molecular diagnostic tests, its ability to retain or secure
reimbursement, its ability to secure additional business and
generate higher profit margins through sales of its molecular
diagnostic tests, in-licensing or other means, projections of
future revenues, growth, gross profit and anticipated internal rate
of return on investments, its ability to maintain its NASDAQ
listing and the Company’s ability to successfully commercialize
BarreGENÒI including collecting clinical data and obtaining
reimbursement. Additionally, all forward-looking statements are
subject to the “Risk Factors” detailed from time to time in the
Company's SEC filings, including its Annual Report on Form 10-K for
the fiscal year ended December 31, 2017, filed on March 23, 2018,
Quarterly Reports on Form 10-Q and other SEC filings. Because of
these and other risks, uncertainties and assumptions, undue
reliance should not be placed on these forward-looking statements.
In addition, these statements speak only as of the date of this
press release and, except as may be required by law, the Company
undertakes no obligation to revise or update publicly any
forward-looking statements for any reason.
CONTACTS:Interpace DiagnosticsInvestor
RelationsJoseph Green / Wiktoria O’Hare646-653-7030 /
7028jgreen@edisongroup.com/ wohare@edisongroup.com
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Apr 2024 to May 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From May 2023 to May 2024